BiotechTube

risperidone + sertraline-primary

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prodromal Schizophrenia

Conditions

Prodromal Schizophrenia, Psychotic Disorders

Trial Timeline

Mar 1, 2004 → Apr 1, 2007

NCT ID
NCT00169988

About risperidone + sertraline-primary

risperidone + sertraline-primary is a pre-clinical stage product being developed by Pfizer for Prodromal Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00169988. Target conditions include Prodromal Schizophrenia, Psychotic Disorders.

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00169988Pre-clinicalCompleted

Competing Products

1 competing product in Prodromal Schizophrenia

See all competitors
ProductCompanyStageHype Score
aripiprazoleBristol Myers SquibbPre-clinical
18